Systematic review with meta‐analysis: risk of post‐operative complications associated with pre‐operative exposure to anti‐tumour necrosis factor agents for Crohn’s disease
Summary Background Post‐operative complications after anti‐tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. Aim To assess the effects of pre‐operative anti‐tumour necrosis factor (TNF) therapy on post‐operative complications within 30 days po...
Saved in:
Published in | Alimentary pharmacology & therapeutics Vol. 49; no. 8; pp. 966 - 977 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Wiley Subscription Services, Inc
01.04.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary
Background
Post‐operative complications after anti‐tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results.
Aim
To assess the effects of pre‐operative anti‐tumour necrosis factor (TNF) therapy on post‐operative complications within 30 days post‐operatively in patients with CD undergoing abdominal surgery.
Methods
Systematic review with meta‐analysis was performed on articles found in MEDLINE, Embase, Cochrane Library, Scopus, and the International Clinical Trials Registry Platform until September 2018.
Results
Twenty studies (7115 patients) were included. Without confounder adjustment, pre‐operative anti‐TNF therapy in patients with CD undergoing abdominal surgery was associated with increased rates of infectious complications (unadjusted odds ratio, OR, 1.49; 95% CI, 1.08‐2.06). After confounder adjustment, Pre‐operative anti‐TNF therapy was significantly associated with both increased rates of total and infectious complications (adjusted OR, 1.53 and 2.09; 95% CI, 1.11‐2.09 and 1.19‐3.65, respectively). After subgroup analyses, the association between anti‐TNF agents and total complications was significant in high incidence countries (adjusted OR, 1.86; 95% CI, 1.43‐2.42) but not in low incidence countries (adjusted OR, 0.77; 95% CI, 0.48‐1.25).
Conclusions
Exposure to anti‐TNF agents is an independent risk factor for post‐operative infectious complications in patients with CD, especially in countries with a high incidence of Crohn's disease. We suggest postponing elective surgery or carefully monitoring these patients post‐operatively. |
---|---|
AbstractList | BACKGROUNDPost-operative complications after anti-tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. AIMTo assess the effects of pre-operative anti-tumour necrosis factor (TNF) therapy on post-operative complications within 30 days post-operatively in patients with CD undergoing abdominal surgery. METHODSSystematic review with meta-analysis was performed on articles found in MEDLINE, Embase, Cochrane Library, Scopus, and the International Clinical Trials Registry Platform until September 2018. RESULTSTwenty studies (7115 patients) were included. Without confounder adjustment, pre-operative anti-TNF therapy in patients with CD undergoing abdominal surgery was associated with increased rates of infectious complications (unadjusted odds ratio, OR, 1.49; 95% CI, 1.08-2.06). After confounder adjustment, Pre-operative anti-TNF therapy was significantly associated with both increased rates of total and infectious complications (adjusted OR, 1.53 and 2.09; 95% CI, 1.11-2.09 and 1.19-3.65, respectively). After subgroup analyses, the association between anti-TNF agents and total complications was significant in high incidence countries (adjusted OR, 1.86; 95% CI, 1.43-2.42) but not in low incidence countries (adjusted OR, 0.77; 95% CI, 0.48-1.25). CONCLUSIONSExposure to anti-TNF agents is an independent risk factor for post-operative infectious complications in patients with CD, especially in countries with a high incidence of Crohn's disease. We suggest postponing elective surgery or carefully monitoring these patients post-operatively. Post-operative complications after anti-tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. To assess the effects of pre-operative anti-tumour necrosis factor (TNF) therapy on post-operative complications within 30 days post-operatively in patients with CD undergoing abdominal surgery. Systematic review with meta-analysis was performed on articles found in MEDLINE, Embase, Cochrane Library, Scopus, and the International Clinical Trials Registry Platform until September 2018. Twenty studies (7115 patients) were included. Without confounder adjustment, pre-operative anti-TNF therapy in patients with CD undergoing abdominal surgery was associated with increased rates of infectious complications (unadjusted odds ratio, OR, 1.49; 95% CI, 1.08-2.06). After confounder adjustment, Pre-operative anti-TNF therapy was significantly associated with both increased rates of total and infectious complications (adjusted OR, 1.53 and 2.09; 95% CI, 1.11-2.09 and 1.19-3.65, respectively). After subgroup analyses, the association between anti-TNF agents and total complications was significant in high incidence countries (adjusted OR, 1.86; 95% CI, 1.43-2.42) but not in low incidence countries (adjusted OR, 0.77; 95% CI, 0.48-1.25). Exposure to anti-TNF agents is an independent risk factor for post-operative infectious complications in patients with CD, especially in countries with a high incidence of Crohn's disease. We suggest postponing elective surgery or carefully monitoring these patients post-operatively. Summary Background Post‐operative complications after anti‐tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. Aim To assess the effects of pre‐operative anti‐tumour necrosis factor (TNF) therapy on post‐operative complications within 30 days post‐operatively in patients with CD undergoing abdominal surgery. Methods Systematic review with meta‐analysis was performed on articles found in MEDLINE, Embase, Cochrane Library, Scopus, and the International Clinical Trials Registry Platform until September 2018. Results Twenty studies (7115 patients) were included. Without confounder adjustment, pre‐operative anti‐TNF therapy in patients with CD undergoing abdominal surgery was associated with increased rates of infectious complications (unadjusted odds ratio, OR, 1.49; 95% CI, 1.08‐2.06). After confounder adjustment, Pre‐operative anti‐TNF therapy was significantly associated with both increased rates of total and infectious complications (adjusted OR, 1.53 and 2.09; 95% CI, 1.11‐2.09 and 1.19‐3.65, respectively). After subgroup analyses, the association between anti‐TNF agents and total complications was significant in high incidence countries (adjusted OR, 1.86; 95% CI, 1.43‐2.42) but not in low incidence countries (adjusted OR, 0.77; 95% CI, 0.48‐1.25). Conclusions Exposure to anti‐TNF agents is an independent risk factor for post‐operative infectious complications in patients with CD, especially in countries with a high incidence of Crohn's disease. We suggest postponing elective surgery or carefully monitoring these patients post‐operatively. |
Author | Wang, Yuan‐Hung Chen, Chiehfeng Lin, Yang‐Sheng Chen, Kee‐Hsin Cheng, Sheng‐Wei Fang, Ching‐Ju |
Author_xml | – sequence: 1 givenname: Yang‐Sheng orcidid: 0000-0001-9135-2543 surname: Lin fullname: Lin, Yang‐Sheng organization: MacKay Medical College – sequence: 2 givenname: Sheng‐Wei surname: Cheng fullname: Cheng, Sheng‐Wei organization: Taipei Municipal Wan Fang Hospital, Taipei Medical University – sequence: 3 givenname: Yuan‐Hung surname: Wang fullname: Wang, Yuan‐Hung email: clifchen@tmu.edu.tw, d508091002@tmu.edu.tw organization: Shuang Ho Hospital, Taipei Medical University – sequence: 4 givenname: Kee‐Hsin surname: Chen fullname: Chen, Kee‐Hsin organization: Wan Fang Hospital, Taipei Medical University – sequence: 5 givenname: Ching‐Ju surname: Fang fullname: Fang, Ching‐Ju organization: National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University – sequence: 6 givenname: Chiehfeng surname: Chen fullname: Chen, Chiehfeng email: clifchen@tmu.edu.tw organization: Wan Fang Hospital, Taipei Medical University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30864199$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kU9u1TAQhy1URF8LCy6ALLGhi7T-kzgxu-oJKFKlIlHW0cSZUJckDrbTx9v1CN1ykF6oJ8ElpRJIeGOP_PmzZn57ZGd0IxLykrNDntYRTPGQF7zKn5AVl6rIBJNqh6yYUDoTFZe7ZC-ES8aYKpl4RnYlq1TOtV6R28_bEHGAaA31eGVxQzc2XtABI9xd38AI_TbY8JZ6G75R19HJhZgu3IQ-PbpCatww9dakwo2BQgjOWIjYLp7J4180_kiC2SONjsIYbbqM8-BmT0c03qWvaAcmOk_hK44xVem49u5ivLv-GWhrA0LA5-RpB33AFw_7Pvny_t35-iQ7PfvwcX18mhlZyDyreNt2WquyZQWXHZqCG5VLyEswFegSpC5UrhtZ5mlUomGm0brRrGSGlQBM7pM3i3fy7vuMIdaDDQb7HkZ0c6gF15xxoZhM6Ot_0MvUVRpfoqTkFS-FFIk6WKj7XoPHrp68HcBva87q-yzrlGX9O8vEvnowzs2A7SP5J7wEHC3Axva4_b-pPv50vih_Ad-dszw |
CitedBy_id | crossref_primary_10_1007_s10620_021_06976_6 crossref_primary_10_1093_ibd_izab165 crossref_primary_10_1097_MEG_0000000000001944 crossref_primary_10_1007_s00595_020_02003_9 crossref_primary_10_3748_wjg_v27_i24_3440 crossref_primary_10_1093_ibd_izac274 crossref_primary_10_1093_ecco_jcc_jjab092 crossref_primary_10_1159_000506898 crossref_primary_10_1002_ags3_12621 crossref_primary_10_1371_journal_pone_0290887 crossref_primary_10_1093_ecco_jcc_jjaa060 crossref_primary_10_1055_a_1713_3941 crossref_primary_10_1111_apt_15384 crossref_primary_10_1007_s10620_021_06895_6 crossref_primary_10_1007_s13304_020_00769_8 crossref_primary_10_1093_ecco_jcc_jjab054 crossref_primary_10_1111_apt_15487 crossref_primary_10_3390_jcm11236884 crossref_primary_10_1177_1756284820931738 crossref_primary_10_1097_DCR_0000000000001716 crossref_primary_10_1016_j_scrs_2020_100749 crossref_primary_10_1093_ibd_izab170 crossref_primary_10_3389_fnins_2019_00877 crossref_primary_10_1093_ecco_jcc_jjac012 crossref_primary_10_1111_apt_15374 crossref_primary_10_1111_apt_15450 crossref_primary_10_3389_fsurg_2022_867830 crossref_primary_10_1080_08941939_2022_2048143 crossref_primary_10_1111_apt_15398 crossref_primary_10_1007_s00384_022_04140_8 crossref_primary_10_1111_apt_15392 crossref_primary_10_1016_j_healun_2021_07_013 |
Cites_doi | 10.1097/SLA.0000000000000757 10.1038/ajg.2012.464 10.1053/j.gastro.2008.01.012 10.1111/j.1365-2036.2004.01904.x 10.1097/SLA.0000000000002017 10.1371/journal.pmed.1000097 10.1097/DCR.0b013e3182a48505 10.1111/j.1463-1318.2010.02469.x 10.1007/s00268-009-9957-x 10.1093/ibd/izy246 10.1002/ibd.3780050209 10.1111/j.1572-0241.2004.04148.x 10.1097/DCR.0b013e31829f682c 10.1136/gut.2010.234617 10.4240/wjgs.v8.i3.274 10.1093/ecco-jcc/jju028 10.1038/ajg.2016.541 10.1007/s10654-010-9491-z 10.1053/j.gastro.2004.01.063 10.1002/ibd.21860 10.1111/j.1572-0241.2004.40304.x 10.1056/NEJMoa0904492 10.1002/bjs.9439 10.1038/ajg.2012.218 10.1046/j.1524-475x.2000.00547.x 10.1053/j.gastro.2013.04.007 10.1016/j.ijsu.2013.12.015 10.1177/2050640615600116 10.3109/00365521.2012.660540 10.1007/s11605-010-1341-5 10.1097/DCR.0b013e3182759029 10.1002/bjs.9152 10.1111/apt.14459 10.1073/pnas.0804812105 10.1016/0197-2456(86)90046-2 10.1007/s11605-008-0646-0 10.1111/apt.12159 10.1590/S0004-28032009000100009 10.1093/clinids/11.6.954 10.1053/j.gastro.2011.11.040 10.1586/17474124.2015.975208 10.1002/sim.1186 10.1136/bmj.315.7109.629 10.1097/MIB.0b013e318281f28f 10.1007/s10620-016-4400-2 10.1038/nature11582 10.1002/ibd.22954 |
ContentType | Journal Article |
Copyright | 2019 John Wiley & Sons Ltd 2019 John Wiley & Sons Ltd. Copyright © 2019 John Wiley & Sons Ltd |
Copyright_xml | – notice: 2019 John Wiley & Sons Ltd – notice: 2019 John Wiley & Sons Ltd. – notice: Copyright © 2019 John Wiley & Sons Ltd |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TK 7U9 H94 M7N 7X8 |
DOI | 10.1111/apt.15184 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2036 |
EndPage | 977 |
ExternalDocumentID | 10_1111_apt_15184 30864199 APT15184 |
Genre | reviewArticle Meta-Analysis Systematic Review Journal Article |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TK 7U9 H94 M7N 7X8 |
ID | FETCH-LOGICAL-c3534-81ddf9967d0513fec51c643a47ac8a97a395649b3740262b0cb99b9070c07aa03 |
IEDL.DBID | DR2 |
ISSN | 0269-2813 |
IngestDate | Fri Aug 16 21:28:37 EDT 2024 Fri Sep 13 05:00:30 EDT 2024 Fri Aug 23 03:05:19 EDT 2024 Tue Aug 27 13:44:22 EDT 2024 Sat Aug 24 00:49:48 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
License | 2019 John Wiley & Sons Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3534-81ddf9967d0513fec51c643a47ac8a97a395649b3740262b0cb99b9070c07aa03 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 |
ORCID | 0000-0001-9135-2543 |
PMID | 30864199 |
PQID | 2331817232 |
PQPubID | 2045200 |
PageCount | 12 |
ParticipantIDs | proquest_miscellaneous_2191012603 proquest_journals_2331817232 crossref_primary_10_1111_apt_15184 pubmed_primary_30864199 wiley_primary_10_1111_apt_15184_APT15184 |
PublicationCentury | 2000 |
PublicationDate | April 2019 2019-04-00 20190401 |
PublicationDateYYYYMMDD | 2019-04-01 |
PublicationDate_xml | – month: 04 year: 2019 text: April 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: Chichester |
PublicationTitle | Alimentary pharmacology & therapeutics |
PublicationTitleAlternate | Aliment Pharmacol Ther |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2017; 62 2015; 261 2012; 142 2009; 46 1997; 315 2004; 126 2010; 14 2013; 108 2011; 60 2018; 267 2000; 8 2013; 145 2013; 100 2008; 12 2010; 362 2012; 18 2011; 13 2008; 105 2015; 9 2017; 112 1999; 5 2012; 107 2011; 7 2018; 47 2016; 4 2012; 491 2013; 19 2004; 99 2009; 33 2013; 37 1989; 11 2003; 327 2010; 25 1986; 7 2004; 19 2013; 56 2015; 21 2019; 25 2009; 6 2012; 47 2008; 134 2012; 21 2016; 8 2014; 12 2014; 101 31359469 - Aliment Pharmacol Ther. 2019 Aug;50(4):467-468 31359474 - Aliment Pharmacol Ther. 2019 Aug;50(4):464-465 31359468 - Aliment Pharmacol Ther. 2019 Aug;50(4):469-470 31591777 - Aliment Pharmacol Ther. 2019 Oct;50(8):969-970 31591780 - Aliment Pharmacol Ther. 2019 Oct;50(8):970-971 31359483 - Aliment Pharmacol Ther. 2019 Aug;50(4):465-466 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_3_1 e_1_2_8_5_1 Chang MI (e_1_2_8_10_1) 2015; 21 e_1_2_8_9_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_41_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 Fascì Spurio F (e_1_2_8_4_1) 2012; 21 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_32_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_40_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 Loftus EV (e_1_2_8_7_1) 2011; 7 e_1_2_8_31_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_52_1 e_1_2_8_50_1 |
References_xml | – volume: 11 start-page: 954 year: 1989 end-page: 963 article-title: Risk of infectious complications in patients taking glucocorticosteroids publication-title: Rev Infect Dis – volume: 18 start-page: 2404 year: 2012 end-page: 2413 article-title: Anti‐tumor necrosis factor and postoperative complications in Crohn's disease: systematic review and meta‐analysis publication-title: Inflamm Bowel Dis – volume: 25 start-page: 603 year: 2010 end-page: 605 article-title: Critical evaluation of the Newcastle‐Ottawa scale for the assessment of the quality of nonrandomized studies in meta‐analyses publication-title: Eur J Epidemiol – volume: 267 start-page: 221 year: 2018 end-page: 228 article-title: Anti‐TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort publication-title: Ann Surg – volume: 99 start-page: 2393 year: 2004 end-page: 2404 article-title: Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis publication-title: Am J Gastroenterol – volume: 107 start-page: 1409 year: 2012 end-page: 1422 article-title: Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow‐up in the TREAT™ registry publication-title: Am J Gastroenterol – volume: 12 start-page: 224 year: 2014 end-page: 230 article-title: Preoperative infliximab use and postoperative complications in Crohn's disease: a systematic review and meta‐analysis publication-title: Int J Surg – volume: 105 start-page: 16731 year: 2008 end-page: 16736 article-title: is an anti‐inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients publication-title: Proc Natl Acad Sci U S A – volume: 8 start-page: 547 year: 2000 end-page: 553 article-title: Inhibition of tumor necrosis factor‐alpha attenuates wound breaking strength in rats publication-title: Wound Repair Regen – volume: 491 start-page: 119 year: 2012 end-page: 124 article-title: Host‐microbe interactions have shaped the genetic architecture of inflammatory bowel disease publication-title: Nature – volume: 46 start-page: 20 year: 2009 end-page: 25 article-title: Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State publication-title: Arq Gastroenterol – volume: 134 start-page: 929 year: 2008 end-page: 936 article-title: Risk factors for opportunistic infections in patients with inflammatory bowel disease publication-title: Gastroenterology – volume: 56 start-page: 1423 year: 2013 end-page: 1433 article-title: The effect of anti‐tumor necrosis factor alpha agents on postoperative anastomotic complications in Crohn's disease: a systematic review publication-title: Dis Colon Rectum – volume: 18 start-page: 1207 year: 2012 end-page: 1213 article-title: Infliximab does not affect postoperative complication rates in Crohn's patients undergoing abdominal surgery publication-title: Inflamm Bowel Dis – volume: 126 start-page: 1504 year: 2004 end-page: 1517 article-title: Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences publication-title: Gastroenterology – volume: 14 start-page: 1859 year: 2010 end-page: 1865 article-title: Perioperative anti‐tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease publication-title: J Gastrointest Surg – volume: 6 start-page: e1000097 year: 2009 article-title: Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement publication-title: PLoS Med – volume: 101 start-page: 539 year: 2014 end-page: 545 article-title: Complications in surgery for Crohn's disease after preoperative antitumour necrosis factor therapy publication-title: Br J Surg – volume: 60 start-page: 1178 year: 2011 end-page: 1181 article-title: Surgery for adult Crohn's disease: what is the actual risk? publication-title: Gut – volume: 47 start-page: 662 year: 2012 end-page: 668 article-title: Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease publication-title: Scand J Gastroenterol – volume: 9 start-page: 293 year: 2015 end-page: 301 article-title: Risk factors for postoperative intra‐abdominal septic complications after surgery in Crohn's disease: a meta‐analysis of observational studies publication-title: J Crohns Colitis – volume: 4 start-page: 784 year: 2016 end-page: 793 article-title: Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: a retrospective international multicentre study publication-title: United Eur Gastroenterol J – volume: 315 start-page: 629 year: 1997 end-page: 634 article-title: Bias in meta‐analysis detected by a simple, graphical test publication-title: BMJ – volume: 62 start-page: 456 year: 2017 end-page: 464 article-title: Tumor necrosis factor alpha inhibitors did not influence postoperative morbidity after elective surgical resections in Crohn's disease publication-title: Dig Dis Sci – volume: 37 start-page: 214 year: 2013 end-page: 224 article-title: Pre‐operative use of anti‐TNF‐α agents and the risk of post‐operative complications in patients with Crohn's disease–a nationwide cohort study publication-title: Aliment Pharmacol Ther – volume: 108 start-page: 583 year: 2013 end-page: 593 article-title: Anti‐tumor necrosis factor therapy is associated with infections after abdominal surgery in Crohn's disease patients publication-title: Am J Gastroenterol – volume: 21 start-page: 1472 year: 2015 end-page: 1477 article-title: A review of the impact of biologics on surgical complications in Crohn's disease publication-title: Inflamm Bowel Dis – volume: 9 start-page: 269 year: 2015 end-page: 272 article-title: Should biologic agents be stopped before surgery for inflammatory bowel disease? publication-title: Expert Rev Gastroenterol Hepatol – volume: 5 start-page: 119 year: 1999 end-page: 133 article-title: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety publication-title: Inflamm Bowel Dis – volume: 56 start-page: 1156 year: 2013 end-page: 1165 article-title: Risk factors for surgical site infection and association with infliximab administration during surgery for Crohn's disease publication-title: Dis Colon Rectum – volume: 25 start-page: 261 year: 2019 end-page: 269 article-title: Meta‐analysis: the influence of preoperative infliximab use on postoperative complications of Crohn's disease publication-title: Inflamm Bowel Dis – volume: 261 start-page: 487 year: 2015 end-page: 496 article-title: The impact of preoperative serum anti‐TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery publication-title: Ann Surg – volume: 145: start-page: 158 issue: ‐ year: 2013 end-page: 165.e152 article-title: Incidence and phenotype of inflammatory bowel disease based on results from the Asia‐pacific Crohn's and colitis epidemiology study publication-title: Gastroenterology – volume: 7 start-page: 3 year: 2011 end-page: 16 article-title: Progress in the diagnosis and treatment of inflammatory bowel disease publication-title: Gastroenterol Hepatol – volume: 8 start-page: 274 year: 2016 end-page: 283 article-title: Post‐operative abdominal complications in Crohn's disease in the biological era: systematic review and meta‐analysis publication-title: World J Gastrointest Surg – volume: 100 start-page: 1089 year: 2013 end-page: 1093 article-title: The effect of immune therapy on surgical site infection following Crohn's disease resection publication-title: Br J Surg – volume: 99 start-page: 878 year: 2004 end-page: 883 article-title: Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy publication-title: Am J Gastroenterol – volume: 362 start-page: 1383 year: 2010 end-page: 1395 article-title: Infliximab, azathioprine, or combination therapy for Crohn's disease publication-title: N Engl J Med – volume: 21 start-page: 67 year: 2012 end-page: 73 article-title: Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? publication-title: J Gastrointestin Liver Dis – volume: 142 start-page: 482 year: 2012 end-page: 489 article-title: Higher predicted vitamin D status is associated with reduced risk of Crohn's disease publication-title: Gastroenterology – volume: 112 start-page: 337 year: 2017 end-page: 345 article-title: Postoperative complications after ileocecal resection in Crohn's disease: a prospective study from the REMIND group publication-title: Am J Gastroenterol – volume: 12 start-page: 1738 year: 2008 end-page: 1744 article-title: Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients publication-title: J Gastrointest Surg – volume: 327 start-page: 557 year: 2003 end-page: 560 article-title: Measuring inconsistency in meta‐analyses publication-title: BMJ – volume: 56 start-page: 449 year: 2013 end-page: 457 article-title: Preoperative infliximab therapy does not increase morbidity and mortality after laparoscopic resection for inflammatory bowel disease publication-title: Dis Colon Rectum – volume: 47 start-page: 573 year: 2018 end-page: 580 article-title: Postoperative outcomes in vedolizumab‐treated Crohn's disease patients undergoing major abdominal operations publication-title: Aliment Pharmacol Ther – volume: 7 start-page: 177 year: 1986 end-page: 188 article-title: Meta‐analysis in clinical trials publication-title: Control Clin Trials – volume: 13 start-page: 1294 year: 2011 end-page: 1298 article-title: Surgical resection in Crohn's disease: is immunosuppressive medication associated with higher postoperative infection rates? publication-title: Colorectal Dis – volume: 19 start-page: 749 year: 2004 end-page: 754 article-title: The risk of post‐operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study publication-title: Aliment Pharmacol Ther – volume: 33 start-page: 1049 year: 2009 end-page: 1052 article-title: Effect of perioperative immunosuppressive medication on early outcome in Crohn's disease patients publication-title: World J Surg – volume: 19 start-page: 1404 year: 2013 end-page: 1410 article-title: Safety of thiopurine therapy in inflammatory bowel disease: long‐term follow‐up study of 3931 patients publication-title: Inflamm Bowel Dis – ident: e_1_2_8_36_1 doi: 10.1097/SLA.0000000000000757 – ident: e_1_2_8_35_1 doi: 10.1038/ajg.2012.464 – ident: e_1_2_8_53_1 doi: 10.1053/j.gastro.2008.01.012 – ident: e_1_2_8_27_1 doi: 10.1111/j.1365-2036.2004.01904.x – ident: e_1_2_8_16_1 doi: 10.1097/SLA.0000000000002017 – ident: e_1_2_8_18_1 doi: 10.1371/journal.pmed.1000097 – ident: e_1_2_8_44_1 doi: 10.1097/DCR.0b013e3182a48505 – ident: e_1_2_8_30_1 doi: 10.1111/j.1463-1318.2010.02469.x – ident: e_1_2_8_39_1 doi: 10.1007/s00268-009-9957-x – ident: e_1_2_8_15_1 doi: 10.1093/ibd/izy246 – ident: e_1_2_8_19_1 doi: 10.1002/ibd.3780050209 – ident: e_1_2_8_26_1 doi: 10.1111/j.1572-0241.2004.04148.x – ident: e_1_2_8_33_1 doi: 10.1097/DCR.0b013e31829f682c – ident: e_1_2_8_5_1 doi: 10.1136/gut.2010.234617 – ident: e_1_2_8_13_1 doi: 10.4240/wjgs.v8.i3.274 – ident: e_1_2_8_11_1 doi: 10.1093/ecco-jcc/jju028 – ident: e_1_2_8_17_1 doi: 10.1038/ajg.2016.541 – ident: e_1_2_8_20_1 doi: 10.1007/s10654-010-9491-z – ident: e_1_2_8_6_1 doi: 10.1053/j.gastro.2004.01.063 – ident: e_1_2_8_32_1 doi: 10.1002/ibd.21860 – ident: e_1_2_8_45_1 doi: 10.1111/j.1572-0241.2004.40304.x – ident: e_1_2_8_50_1 doi: 10.1056/NEJMoa0904492 – ident: e_1_2_8_25_1 doi: 10.1002/bjs.9439 – ident: e_1_2_8_51_1 doi: 10.1038/ajg.2012.218 – volume: 21 start-page: 67 year: 2012 ident: e_1_2_8_4_1 article-title: Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? publication-title: J Gastrointestin Liver Dis contributor: fullname: Fascì Spurio F – ident: e_1_2_8_8_1 doi: 10.1046/j.1524-475x.2000.00547.x – ident: e_1_2_8_43_1 – ident: e_1_2_8_3_1 doi: 10.1053/j.gastro.2013.04.007 – ident: e_1_2_8_14_1 doi: 10.1016/j.ijsu.2013.12.015 – ident: e_1_2_8_37_1 doi: 10.1177/2050640615600116 – ident: e_1_2_8_31_1 doi: 10.3109/00365521.2012.660540 – ident: e_1_2_8_29_1 doi: 10.1007/s11605-010-1341-5 – ident: e_1_2_8_40_1 doi: 10.1097/DCR.0b013e3182759029 – ident: e_1_2_8_42_1 doi: 10.1002/bjs.9152 – ident: e_1_2_8_41_1 doi: 10.1111/apt.14459 – ident: e_1_2_8_46_1 doi: 10.1073/pnas.0804812105 – ident: e_1_2_8_21_1 doi: 10.1016/0197-2456(86)90046-2 – ident: e_1_2_8_24_1 – volume: 21 start-page: 1472 year: 2015 ident: e_1_2_8_10_1 article-title: A review of the impact of biologics on surgical complications in Crohn's disease publication-title: Inflamm Bowel Dis contributor: fullname: Chang MI – ident: e_1_2_8_28_1 doi: 10.1007/s11605-008-0646-0 – ident: e_1_2_8_34_1 doi: 10.1111/apt.12159 – ident: e_1_2_8_48_1 doi: 10.1590/S0004-28032009000100009 – ident: e_1_2_8_52_1 doi: 10.1093/clinids/11.6.954 – ident: e_1_2_8_2_1 doi: 10.1053/j.gastro.2011.11.040 – ident: e_1_2_8_9_1 doi: 10.1586/17474124.2015.975208 – ident: e_1_2_8_22_1 doi: 10.1002/sim.1186 – ident: e_1_2_8_23_1 doi: 10.1136/bmj.315.7109.629 – ident: e_1_2_8_49_1 doi: 10.1097/MIB.0b013e318281f28f – volume: 7 start-page: 3 year: 2011 ident: e_1_2_8_7_1 article-title: Progress in the diagnosis and treatment of inflammatory bowel disease publication-title: Gastroenterol Hepatol contributor: fullname: Loftus EV – ident: e_1_2_8_38_1 doi: 10.1007/s10620-016-4400-2 – ident: e_1_2_8_47_1 doi: 10.1038/nature11582 – ident: e_1_2_8_12_1 doi: 10.1002/ibd.22954 |
SSID | ssj0006702 |
Score | 2.4795732 |
SecondaryResourceType | review_article |
Snippet | Summary
Background
Post‐operative complications after anti‐tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting... Post-operative complications after anti-tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. To assess the... BackgroundPost‐operative complications after anti‐tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results.AimTo... BACKGROUNDPost-operative complications after anti-tumour necrosis agent treatment for Crohn's disease (CD) have been analysed with conflicting results. AIMTo... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 966 |
SubjectTerms | Abdominal surgery Clinical trials Complications Crohn Disease - drug therapy Crohn Disease - surgery Crohn's disease Crohns disease Exposure Health risks Humans Incidence Medical treatment Meta-analysis Patients Postoperative Complications - epidemiology Postoperative Complications - etiology Risk Factors Surgery Systematic review Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor necrosis factor-TNF Tumors |
Title | Systematic review with meta‐analysis: risk of post‐operative complications associated with pre‐operative exposure to anti‐tumour necrosis factor agents for Crohn’s disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fapt.15184 https://www.ncbi.nlm.nih.gov/pubmed/30864199 https://www.proquest.com/docview/2331817232/abstract/ https://search.proquest.com/docview/2191012603 |
Volume | 49 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9YwFD6MXQxv1PlZNyWKF970pW-TfkSvxnAMYSK6wS6EkqQnOGRteduC7Go_Ybf7If6h_RJPmrb6KoJ4l5I0TZtzkudpTp4AvCRKYG3ORYjGJqHgtgzzXOYhltrm0mil0a3oHr1PD0_Eu9PkdAPeTHthvD7E_MPNecYwXjsHV7r9xclV0y1ousqdFqgT0nOA6ONP6ag0G-INiWLIMM6XfFQVclE8853rc9EfAHMdrw4TzsEd-Dw11ceZfF30nV6Yi99UHP_zXe7C7RGIsj1vOduwgdU92Doal9rvw_dPs8Yz8_tbmPtny86xUzeXV2oUM3nNXHA6qy1r6rajjLpBLybO1qLVmRrtAEtfT7PCtdL4jSroV8i6mlFvn1Fm159TK1mF7vOdtcyfDcSU2w1GV5TcX9VfqpvL65aNC00P4OTg7fH-YTie8RAanpCJEFwuLXGurKTRgVs0ydIQSFIiUyZXMlOcCJyQmmdEdNNYR0ZLqYnRRybKlIr4Q9is6gofA0sUlgRP0pJuFRKlk7WhtBWx2x4sbAAvpt4uGi_lUUwUiDqgGDoggN3JDorRm9si5jTyEdLjcQDP52zyQ7e4oiqseypDxJcm-zTiATzy9jM_hRNvFEspA3g1WMHfH1_sfTgeEk_-vegO3CIUJ3040S5sdqsenxJS6vSzwSV-ADdyGHU |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qRSpsSlsoTWmpQSzYZJSJnYcRm6qiGqBTIZhK3aDIdmxRoSbRTCIhVv2EbvkQfqhfwnWcBAaEhNg5suM8fK99jn19DPAMKYExKWW-VibyGTW5n6Y89XUuTcqVFFLbFd3paTw5Y2_Oo_MVeNnvhXH6EMOEm_WMtr-2Dm4npH_xclHVIxyvUnYLbqO7Ry2hev9TPCpO2ohDJBncD9Mx7XSFbBzPcOvyaPQHxFxGrO2Qc3wPPvYv6yJNPo-aWo7U1990HP_3azZgvcOi5NAZzyas6GIL1qbdavt9-P5hkHkmbosLsdO25FLX4ubqWnR6Ji-IjU8npSFVuagxo6y00xMnSwHrRHSmoHNXTzXXS6X1F6ygmWtSlwQb_AIz6-YS35IU2v6_iwVxxwMRYTeE4RUmj-blp-Lm6tuCdGtND-Ds-NXsaOJ3xzz4ikZoJYiYc4O0K8mxg6BGq2isECcJlgiVCp4IihyOcUkT5LpxKAMlOZdI6gMVJEIEdBtWi7LQO0AioXNEKHGOtzKuuVW2wbRhod0hzIwHT_vmziqn5pH1LAgbIGsbwIO93hCyzqEXWUix80OwR0MPngzZ6Ip2fUUUumywDHJfHO_jgHrw0BnQ8BSK1JGNOffgeWsGf398dvhu1iZ2_73oAdyZzKYn2cnr07eP4C6COu6ii_ZgtZ43eh-BUy0ft_7xA59XHJc |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fT9UwFD9BTIgvKqgwQazGB192s7t2f4pPBLxBFEIUEh5MlrZrAzFsy71bQnjiI_DKB_EL8Uk8Xbfp1ZgY37q067r1nPb3W09_BXiDlMCYlDJfKxP5jJrcT1Oe-jqXJuVKCqntiu7BYbx3wvZPo9MFeNfvhXH6EMMPN-sZ7XhtHbzKzS9OLqp6hNNVyu7BfRbT0Jr07uef2lFx0gYcIsfgfpiOaScrZMN4hlvnJ6M_EOY8YG1nnMkj-Nq31QWafBs1tRypq99kHP_zZR7Dww6Jkm1nOsuwoIsVWDro1tqfwPcvg8gzcRtciP1pSy50Le6ub0SnZrJFbHQ6KQ2pylmNGWWlnZo4mQtXJ6IzBJ27eqqpniutL7GCZqpJXRLs7nPMrJsLbCUptP185zPiDgciwm4HwytM7kzLs-Lu-nZGupWmp3AyeX-8s-d3hzz4ikZoI4iXc4OkK8lxeKBGq2isECUJlgiVCp4IigyOcUkTZLpxKAMlOZdI6QMVJEIE9BksFmWh14BEQueIT-Icb2Vcc6trg2nDQrs_mBkPXve9nVVOyyPrORB2QNZ2gAcbvR1knTvPspDi0IdQj4YevBqy0RHt6ooodNlgGWS-ONvHAfVg1dnP8BSKxJGNOffgbWsFf398tn103Cae_3vRl7B0tDvJPn04_LgODxDRcRdatAGL9bTRLxA11XKz9Y4fUFkbRg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Systematic+review+with+meta%E2%80%90analysis%3A+risk+of+post%E2%80%90operative+complications+associated+with+pre%E2%80%90operative+exposure+to+anti%E2%80%90tumour+necrosis+factor+agents+for+Crohn%E2%80%99s+disease&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=Yang%E2%80%90Sheng+Lin&rft.au=Sheng%E2%80%90Wei+Cheng&rft.au=Yuan%E2%80%90Hung+Wang&rft.au=Kee%E2%80%90Hsin+Chen&rft.date=2019-04-01&rft.pub=Wiley+Subscription+Services%2C+Inc&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=49&rft.issue=8&rft.spage=966&rft.epage=977&rft_id=info:doi/10.1111%2Fapt.15184&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |